By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038Novo NordiskNovo’s obesity blockbuster semagluti...In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity bloc … more ➔
© Niclas Jessen Studio/Bracco Imaging SpAFinancingBlue Therapeutics gets financing to push r...Radiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) … more ➔
EniferNovel FoodEnifer files for EFSA authorisation of myc...As the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA. more ➔
Knowledge Seeker - wikipedia.orgDigital PathologyAIgnostics raises US$34m in Series B finan...Digital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and … more ➔
Resalis/VimeoCollaborationResalis Therapeutics gets equity investmen...Italian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through … more ➔
UCB SApartnershipCancer UK/UCB collaboration: study with 2n...Belgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers. more ➔
123rf.com/IculigAgomabAgomab raises US$89m in Series DAnother strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor. more ➔
Rentschler Biopharma SEBiomanufacturingRentschler with double-digit investment in...Rentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim. more ➔
Roche, Herzog&De MeuronAlzheimer’s DiseaseRoche leaves Alzheimer partnership with UC...Roche drops a third Alzheimer’s candidate this year, leaving a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease. more ➔
NucleraNuclera Secures US$75m to Advance Protein...Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide. more ➔
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038
© Niclas Jessen Studio/Bracco Imaging SpA
Enifer
Knowledge Seeker - wikipedia.org
Resalis/Vimeo
UCB SA
123rf.com/Iculig
Rentschler Biopharma SE
Roche, Herzog&De Meuron
